[Laryngeal cancer surveillance in heart transplants]

Transplantation of human internal organs is accompanied by the risk of the subsequent occurrence of a malignant neoplasm. The increased incidence of malignant neoplasms is due to immunosuppressive therapy, which leads to impaired immune surveillance for malignant neoplasms, as well as increased susceptibility to oncogenic viruses. We have not found a description of the laryngeal cancer development after heart transplantation in the available literature. Here is our observation. Patient P., 66 years old, was admitted to the department of head and neck tumors of the State Clinical Hospital No. 1 on 05/27/19 with complaints of hoarseness. Based on the examination, the diagnosis of laryngeal cancer cT3N0M0M was established. Anamnesis revealed that due to ischemic cardiomyopathy, post-infarction mitral insufficiency, balloon angioplasty and stenting of the right coronary artery on 17.08.11 and 06.11.13, orthotonic heart transplantation was performed. The clinical situation was discussed with mutual participation of oncologists, radiologists, chemotherapists - a combined treatment plan was developed with preoperative radiation therapy of total focal dose (TFD) 44Gy at the first stage, which was carried out with slight positive dynamics, followed by laryngectomy. The uniqueness of this observation lies in the fact that a patient 6 years after heart transplantation was diagnosed with laryngeal cancer, he underwent combined treatment with neoadjuvant radiation therapy, TFD 44 Gy and an operation in the volume of laryngectomy without complications.